Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1994-10-13
pubmed:abstractText
Using flow cytometry, cellular IL-2 receptors were studied before and following chemoimmunotherapy combination in 20 patients with metastatic malignant melanoma (MMM). Patients received cisplatin (100 mg/m2) at days 1 and 28, recombinant IL-2 by continuous infusion from days 3 to 6, 17 to 21, 31 to 34, and 45 to 49. Interferon-alpha (IFN-alpha) was given subcutaneously three times weekly. In terms of clinical response, we observed 55% objective response (complete: 15%). When pretreatment blood samples were compared with those of healthy donors, we did not observe any change in low (alpha chain) and high affinity receptor (alpha + beta) expression. In contrast, intermediate affinity p75 (beta chain) expression was decreased significantly (P < or = 0.0001) in MMM patients. During treatment, we found a dramatic increase of beta chain as well as high affinity (alpha + beta) expression in responding patients, as soon as IL-2 therapy began. Furthermore, the increase of beta chain expression was limited to natural killer (NK) cells (CD56+). In non-responding patients, on the other hand, increase of both receptors was seen only at day 31. These data suggest the involvement of beta chain expression in the mechanism of cell activation after chemoimmunotherapy. Moreover, this early beta chain expression is correlated with the clinical response to chemoimmunotherapy.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-1500859, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-1596890, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-1691679, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-1692080, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-1698909, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2108515, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2139697, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2317822, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2467946, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2471587, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2673025, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2787381, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-2826541, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-3023487, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-3030546, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-3076761, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-3098894, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-3110786, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-3263508, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-3930598, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-6367046, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-8229131, http://linkedlifedata.com/resource/pubmed/commentcorrection/8082289-8306497
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0009-9104
pubmed:author
pubmed:issnType
Print
pubmed:volume
97
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
342-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma.
pubmed:affiliation
Department of Medical Oncology, Salpetrière Hospital, Paris, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't